Cyclerion Therapeutics, Inc. financial data

Symbol
CYCN on Nasdaq
Industry
Pharmaceutical Preparations
Location
301 Binney Street, Cambridge, Massachusetts
State of incorporation
Massachusetts
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 287 % +25.7%
Return On Equity 1.52 %
Return On Assets 1.19 %
Operating Margin 158 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.71 M shares -93.8%
Common Stock, Shares, Outstanding 2.5 M shares -94.3%
Entity Public Float 7.1 M USD -62.2%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 2.49 M shares +14.6%
Weighted Average Number of Shares Outstanding, Diluted 2.49 M shares +14.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD -100%
Research and Development Expense 987 K USD -92.3%
General and Administrative Expense 7 M USD -39.7%
Operating Income (Loss) -11.3 M USD -27.9%
Nonoperating Income (Expense) 346 K USD -7.98%
Net Income (Loss) Attributable to Parent 149 K USD +77.8%
Earnings Per Share, Basic 0.33 USD/shares +80.6%
Earnings Per Share, Diluted 0.33 USD/shares +80.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.7 M USD -20.5%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Other Assets, Current 10 K USD -98%
Assets, Current 6.01 M USD -27.8%
Other Long-term Investments 5.35 M USD
Property, Plant and Equipment, Net 0 USD
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 11.4 M USD -0.8%
Accounts Payable, Current 741 K USD -81.1%
Liabilities, Current 1.44 M USD -80.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -16 K USD +15.8%
Retained Earnings (Accumulated Deficit) -266 M USD +0.06%
Stockholders' Equity Attributable to Parent 9.92 M USD +153%
Liabilities and Equity 11.4 M USD -0.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.87 M USD +69.9%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 20 M shares -95%
Common Stock, Shares, Issued 2.71 M shares -93.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.88 M USD +69.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.7 M USD -20.5%
Deferred Tax Assets, Valuation Allowance 82.4 M USD +0.5%
Deferred Tax Assets, Gross 82.4 M USD -0.71%
Property, Plant and Equipment, Gross 126 K USD -94.2%
Deferred Tax Assets, Operating Loss Carryforwards 48.5 M USD +3.09%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 500 K shares
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 822 K USD -83.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares